Y-mAbs Therapeutics (YMAB) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Company overview and strategic focus

• Emphasis on expanding DANYELZA for high-risk neuroblastoma and exploring new indications like osteosarcoma and Ewing sarcoma.

• Business split into two units: commercial/lifecycle management for DANYELZA and radiopharmaceutical development.

• Global expansion underway with partnerships in China, Japan, Brazil, and Mexico, plus direct patient access in Turkey and Europe.

• U.S. market share for DANYELZA at 15-17%, with plans to double in coming years.

• Revenue growth expected, with $88 million reported and ongoing international approvals anticipated.

Radiopharmaceutical platform and clinical development

• SADA PRIT technology enables two-step, pre-targeted radiotherapy, reducing off-target toxicity.

• Two clinical products in development: one targeting CD38 (non-Hodgkin) and one targeting GD2 (sarcoma, melanoma, neuroblastoma).

• GD2-SADA Phase I trial focuses on safety, pharmacokinetics, and visualization of tumor uptake.

• PET imaging to be incorporated in future trial phases for better quantification and patient selection.

• CD38 program benefits from validated patient selection and rapid data-driven development.

Pipeline strategy and future outlook

• Strategic review narrowed 1,200 potential targets to 40-50 high-value candidates, focusing on three franchise areas.

• Targets outside core franchises may be partnered for commercialization.

• Pipeline expansion planned over a three-year horizon, with a dynamic approach to prioritizing and advancing targets.

• Ongoing optimization and reprioritization expected as new data emerges from clinical programs.

• Upcoming Q2 updates will clarify platform progress and long-term strategy.